MK-0476
Asthma
Organon and CoUNKNOWNPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Asthma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Budesonide New York City Health and Hospitals Corporation | Phase 4 | BBB |
SALMETEROL Mundipharma (China) Pharmaceutical Co. Ltd | Phase 4 | BBB |
Montelukast Kafrelsheikh University | Phase 4 | BBB |
Flixotide GlaxoSmithKline | Phase 4 | BBB |
Beclomethasone New York City Health and Hospitals Corporation | Phase 4 | BB |
View all 47 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →